Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A

被引:54
作者
Gialitakis, M
Kretsovali, A
Spilianakis, C
Kravariti, L
Mages, J
Hoffmann, R
Hatzopoulos, AK
Papamatheakis, J [1 ]
机构
[1] FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Greece
[2] Univ Crete, Dept Biol, Iraklion 71110, Greece
[3] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA
[4] Tech Univ, Inst Med Microbiol, D-81675 Munich, Germany
[5] Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany
[6] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37232 USA
[7] GSF Munich, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany
关键词
D O I
10.1093/nar/gkj462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The deacetylase inhibitor Trichostatin A (TSA) induces the transcription of the Major Histocompatibility Class II (MHC II) DRA gene in away independent of the master coactivator CIITA. To analyze the molecular mechanisms by which this epigenetic regulator stimulates MHC II expression, we used chromatin immunoprecipitation (ChIP) assays to monitor the alterations in histone modifications that correlate with DRA transcription after TSA treatment. We found that a dramatic increase in promoter linked histone acetylation is followed by an increase in Histone H3 lysine 4 methylation and a decrease of lysine 9 methylation. Fluorescence recovery after photobleaching (FRAP) experiments showed that TSA increases the mobility of HDAC while decreasing the mobility of the class II enhanceosome factor RFX5. These data, in combination with ChIP experiments, indicate that the TSA-mediated induction of DRA transcription involves HDAC relocation and enhanceosome stabilization. In order to gain a genome-wide view of the genes responding to inhibition of deacetylases, we compared the transcriptome of B cells before and after TSA treatment using Affymetrix microarrays. This analysis showed that in addition to the DRA gene, the entire MHC II family and the adjacent histone cluster that are located in chromosome 6p21-22 locus are strongly induced by TSA. A complex pattern of gene reprogramming by TSA involves immune recognition, antiviral, apoptotic and inflammatory pathways and extends the rationale for using Histone Deacetylase Inhibitors (HDACi) to modulate the immune response.
引用
收藏
页码:765 / 772
页数:8
相关论文
共 37 条
[1]   Nonclassical MHC class II molecules [J].
Alfonso, C ;
Karlsson, L .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :113-+
[2]   CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter [J].
Beresford, GW ;
Boss, JM .
NATURE IMMUNOLOGY, 2001, 2 (07) :652-657
[3]   Pulmonary lactate release in patients with sepsis and the adult respiratory distress syndrome [J].
Brown, SD ;
Clark, C ;
Gutierrez, G .
JOURNAL OF CRITICAL CARE, 1996, 11 (01) :2-8
[4]   Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression [J].
Chang, CH ;
Guerder, S ;
Hong, SC ;
vanEwijk, W ;
Flavell, RA .
IMMUNITY, 1996, 4 (02) :167-178
[5]   Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells [J].
Chou, SD ;
Khan, ANH ;
Magner, WJ ;
Tomasi, TB .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (11) :1483-1494
[6]  
Collinge M, 1998, J IMMUNOL, V161, P1589
[7]   Histone and chromatin cross-talk [J].
Fischle, W ;
Wang, YM ;
Allis, CD .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :172-183
[8]  
Fontes JD, 1999, MOL CELL BIOL, V19, P941
[9]   Comparison of the transcriptional regulation of classical and non-classical MHC class II genes [J].
Hake, SB ;
Tobin, HM ;
Steimle, V ;
Denzin, LK .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (09) :2361-2371
[10]   Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation [J].
Hillman, GG ;
Kallinteris, NL ;
Lu, XQ ;
Wang, Y ;
Wright, JL ;
Li, Y ;
Wu, SZ ;
Forman, JD ;
Gulfo, JV ;
Humphreys, RE ;
Xu, MZ .
CANCER TREATMENT REVIEWS, 2004, 30 (03) :281-290